Xintela AB (XINT) AI Stock Analysis

• Market Cap: €286.12M
• Dividend Yield: N/A
• Average Volume (3M): 554.92K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.61
• Revenue Growth: -7.68%
• EPS Growth: 17.93%
• Country: SE
• Employees: 21
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.02
• Shares Outstanding: 699,564,700
• 10 Day Avg. Volume: 503,836
• 30 Day Avg. Volume: 554,918
• PEG Ratio: 0.10
• Price to Book (P/B): -31.80
• Price to Sales (P/S): 44.88
• P/FCF Ratio: -4.65
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 43 Neutral
• Price Target: ―

Xintela AB's stock is facing significant financial challenges, with persistent losses and negative equity being major concerns. The recent revenue growth is a positive sign but is overshadowed by the company's dependence on external financing and unprofitability. Technical indicators show a mixed outlook, while valuation metrics reflect the company's financial instability. Overall, Xintela AB requires substantial improvement to become a more attractive investment.

Xintela AB Business Overview & Revenue Model

Company Description

Xintela AB (publ), a biomedical company, operates in the fields of regenerative medicine and cancer, focusing on cartilage damage and brain tumors. The company develops products based on XINMARK, a patented marker technology that identifies and selects a range of stem cells, which can develop cartilage cells. It is also developing XSTEM a stem cell product that is in clinical development phase for the treatment of knee osteoarthritis and difficult-to-heal leg ulcers; and EQSTEM, a stem cell product for the treatment of joint diseases in horses, as well as focuses on the preclinical development of therapeutic antibodies for aggressive cancers, including brain tumor glioblastoma and triple negative breast cancer. Xintela AB (publ) was founded in 2009 and is based in Lund, Sweden.

How the Company Makes Money

Xintela AB primarily generates revenue through the development and commercialization of its proprietary cell therapy products and targeted cancer treatments. The company earns money by partnering with pharmaceutical companies and research institutions to co-develop therapies, licensing its technology, and potentially through future product sales once regulatory approvals are secured. Significant factors contributing to its earnings include collaborative agreements, research grants, and strategic partnerships that support the advancement of its clinical programs. Additionally, Xintela may benefit from milestone payments and royalties from commercialized products developed using its technology.

Xintela AB Financial Statement Overview

Summary

Xintela AB shows potential with increased revenue, but persistent operating losses and negative equity highlight financial instability. The company's cash flow is highly dependent on financing activities, and the negative financial ratios suggest a need for structural financial improvements to achieve long-term sustainability.

Income Statement

Xintela AB has shown significant revenue growth from 2023 to 2024, increasing from SEK 78,000 to SEK 4,215,000. However, the company continues to face substantial losses with a negative net profit margin and EBIT margin due to high operating expenses. The gross profit margin is strong at 100% due to the low cost of revenue, but earnings remain negative, indicating profitability challenges.

Balance Sheet

The company has a negative stockholders' equity, indicating financial distress. The debt-to-equity ratio is technically zero due to no debt, but this is overshadowed by the negative equity. The equity ratio is also negative, reflecting more liabilities than assets, posing a risk to financial stability.

Cash Flow

Free cash flow improved slightly due to increased financing, but operating cash flow remains negative, indicating operational cash generation challenges. The company's reliance on external financing is significant, which could affect financial independence in the long-term.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	4.92M	4.21M	78.00K	0.00	0.00	0.00
Gross Profit	4.92M	4.21M	78.00K	-3.79M	-3.50M	-3.57M
EBITDA	-39.19M	-38.90M	-53.47M	-65.28M	-57.11M	-30.33M
Net Income	-40.59M	-39.19M	-54.08M	-66.22M	-58.93M	-52.92M
Balance Sheet
Total Assets	18.24M	24.80M	18.39M	24.52M	24.74M	48.51M
Cash, Cash Equivalents and Short-Term Investments	10.53M	16.68M	7.81M	8.34M	9.94M	33.60M
Total Debt	0.00	0.00	0.00	0.00	0.00	10.90M
Total Liabilities	36.78M	30.75M	14.02M	18.74M	20.80M	20.91M
Stockholders Equity	-18.54M	-5.95M	4.38M	5.78M	3.95M	27.61M
Cash Flow
Free Cash Flow	-29.41M	-40.70M	-53.22M	-39.60M	-44.15M	-21.71M
Operating Cash Flow	-29.34M	-40.70M	-53.12M	-39.49M	-42.89M	-21.33M
Investing Cash Flow	-70.00K	0.00	-104.00K	-27.52M	-1.20M	-329.00K
Financing Cash Flow	39.22M	50.09M	51.79M	64.56M	20.43M	54.85M

Xintela AB Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.26
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For SE:XINT, the sentiment is Negative. The current price of 0.26 is below the 20-day moving average (MA) of 0.33, below the 50-day MA of 0.39, and below the 200-day MA of 0.40, indicating a bearish trend. The MACD of -0.04 indicates Positive momentum. The RSI at 31.88 is Neutral, neither overbought nor oversold. The STOCH value of 36.76 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for SE:XINT.

Xintela AB Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ELIC	47 Neutral	kr257.24M	―	―	―	―	53.48%
XINT	43 Neutral	€286.12M	-6.33	―	―	-7.68%	17.93%
MODTX	42 Neutral	€47.80M	-2.16	-1117.29%	―	―	21.80%
IRLAB.A	38 Underperform	€204.70M	-1.53	-199.86%	―	69.03%	23.10%
ISOFOL	36 Underperform	kr197.06M	―	-51.35%	―	―	-34.02%
ACTI	32 Underperform	€97.31M	-1.80	-1291.15%	―	―	28.54%